Relationship between immune checkpoint proteins and neoadjuvant chemotherapy response in breast cancer

被引:0
作者
Kilicaslan, Umut Kina
Aru, Basak [1 ]
Aksu, Sibel Aydin [2 ]
Aker, Fugen Vardar [3 ,4 ]
Demirel, Gulderen Yanikkaya [1 ,5 ]
Gurleyik, Meryem Gunay [6 ]
机构
[1] Univ Hlth Sci Turkey, Istanbul Haydarpasa Numune Training & Res Hosp, Dept Gen Surg, Istanbul, Turkiye
[2] Yeditepe Univ, Fac Med, Dept Immunol, Istanbul, Turkiye
[3] Univ Hlth Sci Turkey, Istanbul Haydarpasa Numune Training & Res Hosp, Dept Radiol, Istanbul, Turkiye
[4] Univ Hlth Sci Turkey, Istanbul Haydarpasa Numune Training & Res Hosp, Dept Pathol, Istanbul, Turkiye
[5] Yeditepe Univ, 26 Agustos Yerleskesi Tip Fakultesi, TR-34755 Istanbul, Turkiye
[6] Saglik Bilimleri Univ Haydarpasa Numune Egitim ve, Tibbiye Cd 23 Gen Cerrahi Servisi, TR-34668 Istanbul, Turkiye
来源
SURGICAL ONCOLOGY-OXFORD | 2024年 / 52卷
关键词
Breast cancer; CTLA-4; Immune checkpoint proteins; Neoadjuvant chemotherapy; PD-1; TIM-3; PREDICTIVE-VALUE; CD24; EXPRESSION; CD44; IDENTIFICATION; IMMUNOTHERAPY; INFILTRATION; PROGNOSIS; PATHWAY; TIM-3;
D O I
10.1016/j.suronc.2024.102037
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Following major developments in cancer immunotherapy, treatments targeting immune checkpoint proteins (ICP) gained interest in breast cancer, though studies mostly focus on patients with metastatic disease as well as patients nonresponsive to the conventional treatments. Herein, we aimed to investigate the levels of ICP in tumor stroma and tumor infiltrating lymphocytes, and tumor tissue prior to neoadjuvant chemotherapy administration to evaluate the relationship between ICP levels, clinicopathological parameters, and NAC response. Materials and methods: This study was conducted with 51 patients where PD-1, PD-L1, CTLA-4, TIM-3, CD24 and CD44 levels were investigated in CD45+ cells while CD326, CD24, CD44 and PD-L1 protein expression levels were investigated in CD45- population. In addition, CD44 and CD24 levels were evaluated in the tumor stroma. TIL levels were investigated according to the TILS Working Group. Treatment responses after NAC were evaluated according to the MD Anderson RCB score. Results: Our results revealed positive correlation between CTLA-4 and CD44 expression in cases with high TIL levels as well as TIL levels and CTLA-4 expression in cases with partial response. Similarly, positive correlation was detected between TIM3 and PD-L1 levels in cases with good response. In addition, a negative correlation between TILs after NAC and PD-1/PD-L1 expression in lymphocytes in cases with partial complete response. Conclusions: Our study provides preliminary data about the correlation between ICP and clinicopathological status and NAC response in breast cancer, in addition to underlining the requirement for further research to determine their potential as therapeutic targets.
引用
收藏
页数:8
相关论文
共 67 条
[1]   Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[2]   Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update [J].
Allison, Kimberly H. ;
Hammond, M. Elizabeth H. ;
Dowsett, Mitchell ;
McKernin, Shannon E. ;
Carey, Lisa A. ;
Fitzgibbons, Patrick L. ;
Hayes, Daniel F. ;
Lakhani, Sunil R. ;
Chavez-MacGregor, Mariana ;
Perlmutter, Jane ;
Perou, Charles M. ;
Regan, Meredith M. ;
Rimm, David L. ;
Symmans, W. Fraser ;
Torlakovic, Emina E. ;
Varella, Leticia ;
Viale, Giuseppe ;
Weisberg, Tracey F. ;
McShane, Lisa M. ;
Wolff, Antonio C. .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (12) :1346-+
[3]   Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression [J].
Asano, Yuka ;
Kashiwagi, Shinichiro ;
Goto, Wataru ;
Takada, Koji ;
Takahashi, Katsuyuki ;
Morisaki, Tamami ;
Fujita, Hisakazu ;
Takashima, Tsutomu ;
Tomita, Shuhei ;
Ohsawa, Masahiko ;
Hirakawa, Kosei ;
Ohira, Masaichi .
JOURNAL OF TRANSLATIONAL MEDICINE, 2018, 16
[4]  
Baaten Bas Jg, 2010, Commun Integr Biol, V3, P508, DOI 10.4161/cib.3.6.13495
[5]   Tumor-infiltrating lymphocyte composition, organization and PD-1/PD-L1 expression are linked in breast cancer [J].
Buisseret, Laurence ;
Garaud, Soizic ;
de Wind, Alexandre ;
Van den Eynden, Gert ;
Boisson, Anais ;
Solinas, Cinzia ;
Gu-Trantien, Chunyan ;
Naveaux, Celine ;
Lodewyckx, Jean-Nicolas ;
Duvillier, Hugues ;
Craciun, Ligia ;
Veys, Isabelle ;
Larsimont, Denis ;
Piccart-Gebhart, Martine ;
Stagg, John ;
Sotiriou, Christos ;
Willard-Gallo, Karen .
ONCOIMMUNOLOGY, 2017, 6 (01)
[6]   TIM-3 expression in breast cancer [J].
Burugu, Samantha ;
Gao, Dongxia ;
Leung, Samuel ;
Chia, Stephen K. ;
Nielsen, Torsten O. .
ONCOIMMUNOLOGY, 2018, 7 (11)
[7]   TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer [J].
Cabioglu, Neslihan ;
Onder, Semen ;
Oner, Gizem ;
Karatay, Huseyin ;
Tukenmez, Mustafa ;
Muslumanoglu, Mahmut ;
Igci, Abdullah ;
Eralp, Yesim ;
Aydiner, Adnan ;
Saip, Pinar ;
Yavuz, Ekrem ;
Ozmen, Vahit .
BMC CANCER, 2021, 21 (01)
[8]   The Hyaluronan/CD44 Axis: A Double-Edged Sword in Cancer [J].
Cirillo, Nicola .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (21)
[9]   Tim-3 and its role in regulating anti-tumor immunity [J].
Das, Madhumita ;
Zhu, Chen ;
Kuchroo, Vijay K. .
IMMUNOLOGICAL REVIEWS, 2017, 276 (01) :97-111
[10]   Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer [J].
Denkert, Carsten ;
Loibl, Sibylle ;
Noske, Aurelia ;
Roller, Marc ;
Mueller, Berit Maria ;
Komor, Martina ;
Budczies, Jan ;
Darb-Esfahani, Silvia ;
Kronenwett, Ralf ;
Hanusch, Claus ;
von Toerne, Christian ;
Weichert, Wilko ;
Engels, Knut ;
Solbach, Christine ;
Schrader, Iris ;
Dietel, Manfred ;
von Minckwitz, Gunter .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) :105-113